Chitosan nanoparticles for ocular delivery of cyclosporine A

Journal of Microencapsulation

Volumn 31, Issue 1, 2014, Pages 49-57

  Başaran, Ebru ^a   Yenilmez, Evrim ^a   Berkman, Murat Sami ^a   Büyükköroǧlu, Gülay ^a   Yazan, Yasemin ^a  

^a ANADOLU UNIVERSITY   (Turkey)

Author keywords

Chitosan nanoparticles; Cyclosporine A; Ocular application

Indexed keywords

CHITOSAN; CYCLOSPORIN A; NANOPARTICLE;

ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; EXPERIMENTAL SHEEP; IN VITRO STUDY; IN VIVO STUDY; LACRIMAL FLUID; LIPOPHILICITY; MOLECULAR WEIGHT; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; SPRAY DRYING; SURFACE PROPERTY; VITREOUS BODY; ZETA POTENTIAL;

ANIMALS; CHITOSAN; CYCLOSPORINE; DELAYED-ACTION PREPARATIONS; EYE; IMMUNOSUPPRESSIVE AGENTS; NANOPARTICLES; SHEEP;

EID: 84893132069     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2013.805839     Document Type: Article

References (47)

1. Agnihotri SA, Mallikarjuna NN, Aminabhavi TA. Recent advances on chitosan-based micro-And nanoparticles in drug delivery. J Control Release 2004;100:5-28
2. Alonso MH, Sanchez A. The potential of chitosan in ocular drug delivery. J Pharm Pharmacol 2003;55:1451-63
3. Asada M, Takahashi H, Okamoto HS, Tanino H, Danjo K. Theophylline particle design using chitosan by the spray drying. Int J Pharm 2004; 270:167-74
4. Attama AA, Reichl S, Mü ller-Goyman CC. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008;355:307-13
5. Augusteyn RC, Cake MA. Post-mortem water uptake by sheep lenses left in situ. Mol Vis 2005;11:749-51
6. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharm 2010;56:290-9
7. Ba̧saran E, Demirel M, Srmagü l B, Yazan Y. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul 2010;27(1):37-47
8. Ba̧saran E, Demirel M, Srmagül B, Yazan, Y. Polymeric cyclosporine-A nanoparticles for ocular application. J Biomed Nanotechnol 2011;7: 1-10
9. Berger J, Reist M, Mayer JM, Felt O, Gurny R. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur J Pharm Biopharm 2004;57:35-52
10. Biagiotti S, Rossi L, Bianchi M, Giacomini E, Pierigè F, Serafini G, Conaldi PG, Magnani M. Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. J Control Release 2011;154:306-13
11. Casimiro MH, Gil MH, Leal JP. Suitability of gamma irradiated chitosan based membranes as matrix in drug release system. Int J Pharm 2010; 395:142-6
12. CEDIA. 2006. Cyclosporine PLUS assay specification sheet. Fremont, VA: Microgenics Corporation
13. Choc G. 2000. Cyclosporine: Pharmacology. In: Yocum DE, ed. Cyclosporine: Clinical application in autoimmune diseases. Philadelphia: Harcourt Health Communications, pp. 15-29
14. Corrigan DO, Healy AM, Corrigan OI. Preparation and release of salbutamol from chitosan and chitosan co-spray dried compacts and multiparticulates. Eur J Pharm Biopharm 2006;62:295-305
15. Dash M, Chiellini F, Ottenbrite RM, Chiellini E. Chitosan-A versatile semi-synthetic polymer in biomedical applications. Prog Polym Sci 2011;36:981-1014
16. De Campos, AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 2001;224: 159-68
17. Gan L, Gan Y, Zhu C, Zhang X, Zhu J. Novel microemulsion in situ electrolyte-Triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: In vitro and in vivo results. Int J Pharm 2009; 365:143-9
18. Gao J, Ding X, Chu C, Lu L, Zhang Y, Chen Y, Fan W, Li G, Gao S. Dry powder inhalations containing thymopentin and its immunomodulating effects in Wistar rats. Eur J Pharm Sci 2009;36:572-9
19. Gibson M, ed. 2004. Ophthalmic dosage forms. In: Pharmaceutical preformulation and formulation. FL, USA: CRC Press LLC, pp. 461-91
20. Gürsoy AZ, ed. 2002. Ocular drug delivery systems (Oküler sistemler). In: Controlled release systems (Kontrollü Sal|m Sistemleri). -Istanbul: Elma Bilgisayar Basim ve Ambalaj San. Tic. Ltd. Sti., pp. 197-217
21. Hägerstrom H, Paulsson M. Edsman K. Evaluation of mucoadhesion for two polyelectrolyte gels in simulated physiological conditions using a rheological method. Eur J Pharm Sci 2000;9:301-9
22. Hagigit T, Abdulrazik M, Orucov F, Valamanesh F, Lambert M, Lambert G, Behar-Cohen F, Benita S. Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye. J Control Release 2010;145:297-305
23. He P, Davis SS, Illum L. Chitosan microspheres prepared by spray drying. Int J Pharm 1999;187(1):53-65
24. Hirunpanich V, Sugiyama E, Sato H. Ethyl docosahexaenoate decreased Neoral- absorption due to particle size enlargement. Int J Pharm 2008; 361:251-2
25. Jenning V, Mäder K, Gohla S.H. Solid lipid nanoparticles (SLNTM) based on binary mixtures of liquid and solid lipids: A 1H-NMR study. Int J Pharm 2000b;205:15-21
26. Jenning V, Thünemann AF, Gohla SH. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 2000a;199:167-77
27. Johnston TP, Dias CS, Mitra AK. 2003. Mucoadhesive polymers in ophthalmic drug delivery. In: Mitra AK, ed. Ophthalmic drug delivery systems. NY, USA: Marcel Dekker Inc., pp. 409-35
28. Khor E, Lim LY. Implantable applications of chitin and chitosan. Biomaterials 2003;24(13):2339-49
29. Kim B-G, Kang I-J. Evaluation of the effects of biodegradable nanoparticles on a vaccine delivery system using AFM, SEM, and TEM. Ultramicroscopy 2008;108:1168-73
30. Kumar M, Singhal SK, Singh A. Development and validation of a stability indicating HPLC assay method for cyclosporine in cyclosporine oral solution USP. J Pharmaceut Biomed 2001;25(1):9-14
31. Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporine A delivery to the eye: A pharmaceutical challenge. Eur J Pharm Biopharm 2003;56:307-18
32. Li Y, Wong HL, Shuhendler AJ, Rauth AM, Wu XY. Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles. J Control Release 2008; 128:60-70
33. Loh JW, Saunders M, Lim L-Y. Cytotoxicity of monodispersed chitosan nanoparticles against the Caco-2 cells. Toxicol Appl Pharm 2012;262: 273-82
34. Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011;403:185-91
35. Mahmoud AA, El-Feky GS, Kamel R, Awad GEA. Chitosan/sulfobutylether- cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 2011;413:229-36
36. Manjunath K, Reddy JS, Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Method Find Exp Clin 2005;278(2):127-44
37. Müller RH, Runge SA, Ravelli V, Mehnert W, Thünemann AF, Souto E.B. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN-) versus drug nanocrystals. Int J Pharm 2006;317:82-9
38. Pignatello R, Ferro M, De Guidi G, Salemi G, Vandelli M.A, Guccione S, Geppi M, Forte C, Puglisi C. Preparation, characterisation and photosensitivity studies of solid dispersions of diflunisal and Eudragit RS100- and RL100-. Int J Pharm 2001;218:27-42
39. Rao SB, Sharma CP. Use of chitosan as a biomaterial: Studies on its safety and hemostatic potential. J Biomed Mater Res 1997;34:21-8
40. Saito Y, Iwata T. Characterization of hydroxyl groups of highly crystalline b-chitin under static tension detected by FT-IR. Carbohyd Polym 2012;87:2154-9
41. Shen J, Deng Y, Jin X, Ping Q, Su Z, Li L. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution. Int J Pharm 2010;402:248-53
42. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, Dhawan S. Chitosan microspheres as a potential carrier for drugs. Int J Pharm 2004;274:1-33
43. Sionkowska A, Wisniewski M, Skopinska J, Kennedy CJ, Wess TJ. Molecular interactions in collagen and chitosan blends. Biomaterials 2004;25:795-801
44. Sormoli ME, Islam MIU, Langrish TAG. The effect of chitosan hydrogen bonding on lactose crystallinity during spray drying. J Food Eng 2012; 108:541-8
45. Spellicy CJ, Daiger SP, Zhu J, Liu Q, Pierce EA, Sullivan LS, Bowne SJ. Characterization of retinal inosine monophosphate dehydrogenase 1 in several mammalian species. Mol Vis 2007;13:1866-72
46. Tang H, Zhang P, Kieft TL, Ryan SJ, Baker SM, Wiesmann WP, Rogelj S. Antibacterial action of a novel functionalized chitosan-Arginine against gram-negative bacteria. Acta Biomater 2010;6:2562-71
47. Yenilmez E, Ba̧saran E, Yazan Y. Release characteristics of vitamin E incorporated chitosan microspheres and in vitro-in vivo evaluation for topical application. Carbohyd Polym 2011;84:807-11